Ladies and gentlemen, welcome to the chemical circus of SMS Pharmaceuticals Ltd — the company that cooks APIs like Indian aunties cook achar: with precision, patience, and occasional burning sensations (mostly on the P&L). As of November 2025, the stock is strutting at ₹289, with a market cap of ₹2,709 crore and a stock P/E of 33.4x. Over the last three months, the stock jumped 29%, proving once again that API chemistry can be as exciting as cricket if you add the right catalysts.
The company’s Q2 FY26 revenue stood at ₹242 crore, up 23.2% YoY, while PAT rose 76% YoY to ₹25 crore. That’s like going from a headache to a dopamine rush — quite fitting for a drug manufacturer. Margins bounced back to 20% OPM, courtesy of better product mix and improved backward integration.
The fun part? Promoters upped their holding to 68.1%, while mutual funds quietly snuck in through the side door. But before you think it’s all sunshine and ibuprofen, remember: 34.6% of promoter holdings are pledged, proving once again that in pharma, leverage isn’t just for molecules.
2. Introduction – How an API Factory Became a Comeback Story
If Bollywood ever made a film about balance sheets, SMS Pharma would be the perfect protagonist — underdog beginnings, volatile middle years, and a fiery comeback. From a quiet Hyderabad-based API maker to one of India’s fastest-growing niche pharmaceutical exporters, this company has mixed science and survival with the same precision as its reaction vessels.
In FY22, the company’s margins took a nosedive — ibuprofen production launched at negative margins, input costs shot up, and analysts lost their patience faster than paracetamol dissolves in water. Yet here we are in FY26, with the company clocking 18–20% EBITDA margins and an 81 crore TTM PAT.
Its recovery isn’t luck. It’s chemistry — backward integration, process efficiency, and a product mix that looks like a doctor’s prescription list: anti-retrovirals, anti-diabetics, anti-migraines, and more. In short, SMS Pharma doesn’t make pills; it makes the raw material for everyone else’s profit pills.
If every pharma company were a student, Sun Pharma would be the overachiever, Dr. Reddy’s the nerd, and SMS Pharma — the smart kid who passes exams by synthesizing the textbook.
3. Business Model – WTF Do They Even Do?
SMS Pharmaceuticals manufactures Active Pharmaceutical Ingredients (APIs) and Intermediates. Think of it as the upstream of pharma — they make the “active” stuff that actually heals, while branded drug companies just package it in fancy tablets and ads with smiling models.
Their API portfolio includes over 45 products across 10+ therapeutic areas, such as anti-retroviral, anti-ulcer, anti-migraine, and anti-diabetic. With 800+ customers across 75+ countries, the company is a behind-the-scenes supplier to giants like Cipla, Teva, Zydus, Alkem, and Johnson & Johnson.
The API segment contributes a massive 98% of revenue, while intermediates are just a supporting cast. The geographic mix is 87% domestic, 13% export — basically, most of their drugs are born and consumed in India itself.
They run two facilities: one at Hyderabad (200 KL) and another at Vizag (3,000 KL). Combined capacity: 3,200 KL — enough to fill a few Olympic swimming pools with chemicals and still have room for margin expansion.
Their 2025–26 capex plan of ₹150 crore focuses on expanding production and completing Phase 2 backward integration (trial runs already done, commercial production from March 2025). In short — less importing, more reacting.
Ever wonder how much research goes into making a molecule profitable? SMS spends 1.5–2% of its revenue on R&D, with 60+ scientists and a joint venture with Spain’s Chemo Iberica.
So yes — while others import chemistry, SMS exports confidence.
Not bad for a company that was once struggling with ibuprofen hangovers. Margins have returned to a solid 20%, and the operating leverage is kicking in like caffeine after a night shift.
The QoQ jump shows that backward integration is no longer a buzzword — it’s literally paying the bills.
5. Valuation Discussion – The Fair Value Range
Let’s apply three lenses — P/E, EV/EBITDA, and DCF — for a sanity check.
Method 1: P/E Multiple Industry P/E ≈ 33x SMS EPS (annualized) = ₹10.72 → Fair value = ₹10.72 × (25–35) = ₹268–₹375 per share
Method 2: EV/EBITDA EV = ₹2,935 crore EBITDA (FY25 TTM) = ₹162 crore EV/EBITDA = 18.1x Peer average = 15–20x → Fair value range (adjusted) = ₹250–₹340 per share
Method 3: DCF (Simplified) Assuming 12% CAGR in free cash flow, 10% discount rate, and 3% terminal growth: → Implied value ≈ ₹280–₹360 per share
Educational Fair Value Range: ₹260 – ₹370
Disclaimer: This fair value range is for educational purposes only and is not investment advice. Please don’t mortgage your lab to buy the stock.
6. What’s Cooking – News, Triggers, Drama
In 2025, SMS Pharma was basically living inside a regulatory Netflix series. June saw USFDA inspections at both Hyderabad and
